Literature DB >> 12543869

The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome.

William C Aird1.   

Abstract

Severe sepsis, defined as sepsis with acute organ dysfunction, is associated with high morbidity and mortality rates. The development of novel therapies for sepsis is critically dependent on an understanding of the basic mechanisms of the disease. The pathophysiology of severe sepsis involves a highly complex, integrated response that includes the activation of a number of cell types, inflammatory mediators, and the hemostatic system. Central to this process is an alteration of endothelial cell function. The goals of this article are to (1) provide an overview of sepsis and its complications, (2) discuss the role of the endothelium in orchestrating the host response in sepsis, and (3) emphasize the potential value of the endothelium as a target for sepsis therapy.

Entities:  

Mesh:

Year:  2003        PMID: 12543869     DOI: 10.1182/blood-2002-06-1887

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  371 in total

1.  Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.

Authors:  Sebastian Nuding; Henning Ebelt; Robert S Hoke; Annette Krummenerl; Andreas Wienke; Ursula Müller-Werdan; Karl Werdan
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

Review 2.  Year in review 2010: Critical Care--Multiple organ dysfunction and sepsis.

Authors:  Etienne de Montmollin; Djillali Annane
Journal:  Crit Care       Date:  2011-12-05       Impact factor: 9.097

3.  Modulation of endothelial monolayer permeability induced by plasma obtained from lipopolysaccharide-stimulated whole blood.

Authors:  A Nooteboom; R P Bleichrodt; T Hendriks
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 4.  Disseminated intravascular coagulation: old disease, new hope.

Authors:  Cheng Hock Toh; Michael Dennis
Journal:  BMJ       Date:  2003-10-25

5.  Bacterial lipoprotein TLR2 agonists broadly modulate endothelial function and coagulation pathways in vitro and in vivo.

Authors:  Hae-Sook Shin; Fengyun Xu; Aranya Bagchi; Elizabeth Herrup; Arun Prakash; Catherine Valentine; Hrishikesh Kulkarni; Kevin Wilhelmsen; Shaw Warren; Judith Hellman
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

6.  Role of circulating fibroblast growth factor-2 in lipopolysaccharide-induced acute kidney injury in mice.

Authors:  Parnell C Mattison; Angel A Soler-García; Jharna R Das; Marina Jerebtsova; Sofia Perazzo; Pingtao Tang; Patricio E Ray
Journal:  Pediatr Nephrol       Date:  2011-09-30       Impact factor: 3.714

7.  Angiopoietin-2 is a potential mediator of endothelial barrier dysfunction following cardiopulmonary bypass.

Authors:  Christian Clajus; Alexander Lukasz; Sascha David; Barbara Hertel; Ralf Lichtinghagen; Samir M Parikh; André Simon; Issam Ismail; Hermann Haller; Philipp Kümpers
Journal:  Cytokine       Date:  2012-07-06       Impact factor: 3.861

8.  Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injury.

Authors:  Xiaoguang Sun; Patrick A Singleton; Eleftheria Letsiou; Jing Zhao; Patrick Belvitch; Saad Sammani; Eddie T Chiang; Liliana Moreno-Vinasco; Michael S Wade; Tong Zhou; Bin Liu; Ioannis Parastatidis; Leonor Thomson; Harry Ischiropoulos; Viswanathan Natarajan; Jeffrey R Jacobson; Roberto F Machado; Steven M Dudek; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-05       Impact factor: 6.914

9.  Low vasopressin and progression of neonatal sepsis to septic shock: a prospective cohort study.

Authors:  Abhishek S Aradhya; Venkataseshan Sundaram; Naresh Sachdeva; Sourabh Dutta; Shiv S Saini; Praveen Kumar
Journal:  Eur J Pediatr       Date:  2020-02-15       Impact factor: 3.183

10.  Intensive insulin therapy protects the endothelium of critically ill patients.

Authors:  Lies Langouche; Ilse Vanhorebeek; Dirk Vlasselaers; Sarah Vander Perre; Pieter J Wouters; Kristin Skogstrand; Troels K Hansen; Greet Van den Berghe
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.